Extended Data Table 6 Adverse events leading to study treatment discontinuation

From: Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial

  1. Safety analysis set included patients who received ≥1 dose of study treatment; includes adverse events (AEs) defined as any AE newly occurring or worsening after the first dose of study treatment to 18 weeks after last dose of study treatment.
  2. AEs leading to study discontinuation by system organ class and preferred term. MedDRA Dictionary (version 24.0) was used for coding AEs.
  3. CMV, cytomegalovirus; GVHD, graft-versus-host disease.
Back to article page